Encompass Health Corp (EHC) company profile
Close on Nov 17, 2026Market cap $13.60BP/E 22.5Yield 0.52%
About Encompass Health
Services-Hospitals, SIC 8060
Encompass Health operates as a provider of inpatient rehabilitation services, owning and managing specialized hospitals dedicated to post-acute recovery. The organization delivers intensive rehabilitative therapy and medical care to individuals recovering from major illnesses and injuries—including strokes, hip fractures, and debilitating neurological conditions—aiming to restore cognitive and physical functioning. Care is delivered through an interdisciplinary model involving specialized nurses, therapists, and case managers utilizing advanced clinical protocols and technology. Nearly all patients enter these facilities via physician referrals following acute-care hospital stays, with Medicare, Medicare Advantage, and managed care plans serving as the primary sources of payment for these nondiscretionary healthcare services.
As of December 31, 2025, the company operated 173 inpatient rehabilitation hospitals comprising 11,465 licensed beds across 39 U.S. states and Puerto Rico, with substantial concentrations in Florida and Texas. It maintains over a third of its hospitals as joint ventures with acute-care systems and owns the real estate for approximately 79% of its hospital facilities. The organization is based in Birmingham, Alabama, where its principal executive offices are located.
Summary of the business section of Encompass Health's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Encompass Health Corp
- Headquarters
- Birmingham, AL
- Address
- 9001 Liberty Parkway 35242
- Phone
- (205) 967-7116
- Website
- encompasshealth.com
- Employees
- 42,000, Dec 31, 2025
- Industry
- Services-Hospitals
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Birmingham, Alabama
Stock & identifiers
- Ticker
- EHC
- Exchange
- NYSE
- IPO date
- Sep 24, 1986
- Shares outstanding
- 99M, Jul 28, 2026
- Public float
- $12.20B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 1-for-5 reverse, Oct 26, 2006; 2-for-1, Mar 18, 1997; 2-for-1, Apr 18, 1995; 3-for-2, Jan 2, 1992
- SEC CIK
- 785161
- CUSIP
- 29261A100
- ISIN
- US29261A1007
- FIGI
- BBG000BGBRG2
- Share class FIGI
- BBG001S5Q5B3
- LEI
- 549300FVRPM9DRQZRG64
- EIN
- 63-0860407
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Mark J. Tarr | President & CEO, Director | 267,814 |
| John Patrick Darby | EVP, Gen Counsel & Secretary | 79,899 |
| Andrew L. Price | Chief Accounting Officer | 69,483 |
| Douglas E. Coltharp | EVP & Chief Financial Officer | 241,368 |
| Patrick William Tuer | EVP, Chief Operating Officer | 24,755 |
| Edmund Fay | Sr. Vice Pres. and Treasurer | 89,325 |
| Elissa Joy Charbonneau | Chief Medical Officer | 17,644 |
| Edward M. Christie III | Director | 9,577 |
| Joan E. Herman | Director | 49,724 |
| Greg D. Carmichael | Director | 20,377 |
| Leslye G. Katz | Director | 49,724 |
| Nancy M. Schlichting | Director | 23,010 |
| Cain A. Hayes | Director | 2,100 |
| Kevin J. O'Connor | Director | 11,600 |
| Christopher R. Reidy | Director | 18,081 |
| Terrance Williams | Director | 16,887 |
| Patricia Anne Maryland | Director | 14,764 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $10.30M | $20.62M | $2.87M | $170 | $113 |
| FY2024 | $9.30M | $17.93M | $2.20M | $147 | $95 |
| FY2023 | $8.84M | $14.07M | $2.83M | $106 | $93 |
| FY2022 | $7.74M | $9.87M | $1.93M | $94 | $88 |
| FY2021 | $8.25M | $6.23M | $2.32M | $80 | $110 |
| FY2020 | $6.93M | $8.45M | $2.27M | $121 | $134 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Mark J. Tarr President and Chief Executive Officer | $1.10M | $5.29M | $1.17M | $2.58M | $164.98K | $10.30M | +11% |
| Patrick W. Tuer Executive Vice President and Chief Operating Officer | $550.00K | $1.43M | – | $786.86K | $81.43K | $2.84M | – |
| Douglas E. Coltharp Executive Vice President and Chief Financial Officer | $750.00K | $1.98M | $437.01K | $1.30M | $48.28K | $4.52M | +17% |
| Patrick Darby Executive Vice President, General Counsel and Secretary | $625.00K | $963.69K | $212.46K | $869.20K | $11.75K | $2.68M | +5% |
| Elissa J. Charbonneau Chief Medical Officer | $435.00K | $518.45K | – | $453.72K | $37.41K | $1.44M | +12% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we employed over 42,000 individuals.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?